Who is sponsoring NCT03977077?

NCT03977077 is sponsored by Henan Cancer Hospital.

What drugs are being tested in NCT03977077?

Interventions in NCT03977077: Albumin binding taxol.

What condition does NCT03977077 study?

NCT03977077 studies Advanced Gastrointestinal Tumors.

Is NCT03977077 still recruiting?

NCT03977077 is currently status unknown. Last updated 6 June 2019.

Last reviewed 2019-06-06 · How we verify

NCT03977077

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of Advanced Gastrointestinal Tumors With Albumin Taxol

Status unknown NA Last updated 6 June 2019

What this trial tests

NA trial testing Albumin binding taxol in Advanced Gastrointestinal Tumors in 100 participants. Status unknown.

Timeline

1 June 2019

Primary endpoint
31 October 2019

31 October 2020

Quick facts

Lead sponsor	Henan Cancer Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 June 2019
Primary completion	31 October 2019
Estimated completion	31 October 2020
Sites	1 location across China

Drugs / interventions tested

Albumin binding taxol — full drug profile →

Conditions studied

Advanced Gastrointestinal Tumors — all drugs for Advanced Gastrointestinal Tumors →

Sponsor

Henan Cancer Hospital

Who can join

Adults 18 to 75, any sex, with Advanced Gastrointestinal Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study was to evaluate the safety and efficacy of domestic injection paclitaxel (albumin binding type) in patients with advanced digestive tract tumors,and to further explore the possible predictors of efficacy.In order to provide more effective chemotherapeutic drugs, prolong survival time and improve quality of life for patients with advanced digestive tract tumors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Henan Cancer Hospital trials

Trials by the same sponsor.

NCT07442890 — A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Ro · NA · not yet recruiting
NCT07472621 — Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma · not yet recruiting
NCT07459608 — Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma · Phase 2 · not yet recruiting
NCT07400575 — Anlotinib in Cross-line Treatment of NSCLC and SCLC · not yet recruiting
NCT07332221 — Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03977077 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Henan Cancer Hospital
Last refreshed: 6 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03977077.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing